WuXi PharmaTech Announces Second-Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
William Blair Downgrades WuXi PharmaTech (WX) to Market Perform
August 17, 2015 7:36 AM EDTWilliam Blair downgraded WuXi PharmaTech (NYSE: WX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.
Shares of WuXi PharmaTech closed at $43.86 yesterday.
... MoreWuXi PharmaTech (WX) Enters $46/ADS Merger Agreement
August 14, 2015 6:36 AM EDTWuXi PharmaTech (NYSE: WX) announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.
Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to US$5.75 per ordinary share of the Company (each, a "Share") and US$46 per American Depositary Share of the Company, each representing eight Shares (each, an "ADS"), or approximately US$3.3 billion in aggregate cash consideration. This represents a 16.5%... More
WuXi PharmaTech (WX) Misses Q2 EPS by 1c, Reconfirms FY Rev Guidance
August 13, 2015 4:32 PM EDTWuXi PharmaTech (NYSE: WX) reported Q2 EPS of $0.38, $0.01 worse than the analyst estimate of $0.39. Revenue for the quarter came in at $194.1 million versus the consensus estimate of $195.26 million.
Full-Year 2015 Financial Guidance
WuXi PharmaTech reconfirms full-year 2015 revenue guidance of $790-$800 million. The company withdraws its... More
